Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Lee Cohn A"'
Autor:
Sandra Tong-Starksen, Paul S. Lin, Brian L. West, Paul Severson, Xin Ye, Heather L. Gelhorn, Charles Peterfy, Henry H. Hsu, Eric Sherman, Fadi Braiteh, Andrew J. Wagner, Gregory M. Cote, Igor Puzanov, Zev A. Wainberg, Vicki L. Keedy, Geoffrey I. Shapiro, Allen Lee Cohn, Bartosz Chmielowski, John H. Healey, Chao Zhang, Mike Sterba, Stephen Patrick Anthony, Arun S. Singh, William D. Tap
Purpose:To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity.P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c23a45df4ab5ad4ce47e4769969c45
https://doi.org/10.1158/1078-0432.c.6530892
https://doi.org/10.1158/1078-0432.c.6530892
Autor:
Sandra Tong-Starksen, Paul S. Lin, Brian L. West, Paul Severson, Xin Ye, Heather L. Gelhorn, Charles Peterfy, Henry H. Hsu, Eric Sherman, Fadi Braiteh, Andrew J. Wagner, Gregory M. Cote, Igor Puzanov, Zev A. Wainberg, Vicki L. Keedy, Geoffrey I. Shapiro, Allen Lee Cohn, Bartosz Chmielowski, John H. Healey, Chao Zhang, Mike Sterba, Stephen Patrick Anthony, Arun S. Singh, William D. Tap
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e149a7afcdc68bbe63a27f167cc400b
https://doi.org/10.1158/1078-0432.22482318.v1
https://doi.org/10.1158/1078-0432.22482318.v1
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560f50f96435950099b910b1a10224ee
https://doi.org/10.1016/s1470-2045(21)00241-2
https://doi.org/10.1016/s1470-2045(21)00241-2
Autor:
Cristina Suarez, Mario Sznol, Richard W. Joseph, Beiying Ding, Ning Leng, Alain Ravaud, John D. Hainsworth, Thomas E. Hutson, Brian I. Rini, David F. McDermott, Sergio Bracarda, Sumanta K. Pal, Allen Lee Cohn, Thomas Powles, Walter M. Stadler, James A. Reeves, Mahrukh Huseni, Christina Schiff, Lawrence Fong, Bernard Escudier, Kenji Hashimoto, Toni K. Choueiri, Michael B. Atkins, Robert J. Motzer
Publikováno v:
European Urology. 79:665-673
Background The use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively. Objective To eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd4b5731294d1d03ff6daf0d1a9584b
https://doi.org/10.1016/j.eururo.2021.01.003
https://doi.org/10.1016/j.eururo.2021.01.003
Autor:
Matthew H. Taylor, Vicky Makker, Mark Messing, Allen Lee Cohn, Robert Orlowski, Corina E. Dutcus, Marcia S. Brose, Lea Dutta, Margarita Romeo, Carol Aghajanian, Raquel Bratos, Emmett V. Schmidt, Jie Huang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundLenvatinib is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. Pembrolizumab is an anti-programmed death-1 monoclonal antibody. We previously reported results from a cohort of 108 patients with metastatic EC (data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fff87288d379a3471d593d0c2abab2e1
https://doaj.org/article/25fb2fd9e17d4770b2699ba5010504c8
https://doaj.org/article/25fb2fd9e17d4770b2699ba5010504c8
Autor:
Paul S. Lin, Charles Peterfy, Andrew J. Wagner, John H. Healey, Mike Sterba, Gregory M. Cote, Paul Severson, Heather L. Gelhorn, Eric J. Sherman, Chao Zhang, Henry H. Hsu, Geoffrey I. Shapiro, Arun S. Singh, Sandra Tong-Starksen, Stephen P. Anthony, Bartosz Chmielowski, Fadi Braiteh, Allen Lee Cohn, Igor Puzanov, William D. Tap, Brian L. West, Vicki L. Keedy, Xin Ye, Zev A. Wainberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 2
Purpose: To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f09343ab321622061b5ecb1934239019
https://pubmed.ncbi.nlm.nih.gov/34716196
https://pubmed.ncbi.nlm.nih.gov/34716196
Autor:
Sujana Movva, Alexander I. Spira, Erika P. Hamilton, Judy S. Wang, Allen Lee Cohn, James F. Strauss, Silvia Stacchiotti, Chris Tucci, John Kauh, Shivani Nanda, Marek K. Kania, Shreyaskumar Patel
Publikováno v:
Journal of Clinical Oncology. 40:11557-11557
11557 Background: Surufatinib is an inhibitor of VEGFR1, 2, & 3, FGFR1, and CSF-1R. A manageable safety profile, and statistically significant improvement in progression-free survival (PFS) in patients (pts) treated with surufatinib have previously b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18b6767139fc32c12c1260d03b98331c
https://doi.org/10.1200/jco.2022.40.16_suppl.11557
https://doi.org/10.1200/jco.2022.40.16_suppl.11557
Autor:
Rosanna Lapham, Charles Swanton, Jianjun Gao, David Cosgrove, Eric A. Klein, Allen Lee Cohn, G. Chung, Nathan Hunkapiller, Donald A. Richards, Kathryn N. Kurtzman, Jessica M. Clement, Minetta C. Liu, Arash Jamshidi, Michael V. Seiden, M.K. Tummala
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(9)
Background A multi-cancer early detection (MCED) test used to complement existing screening could increase the number of cancers detected through population screening, potentially improving clinical outcomes. The Circulating Cell-free Genome Atlas st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099e1439bdd52edb3ea4bef93b187dc5
https://pubmed.ncbi.nlm.nih.gov/34655543
https://pubmed.ncbi.nlm.nih.gov/34655543
Autor:
Timothy C. Rodell, Claire Coeshott, Kristi McIntyre, Joanna Roder, Heinrich Roder, David Apelian, Frank E. Harrell, Allen Lee Cohn, Tanios Bekaii-Saab, William E. Fisher, Alexander S. Rosemurgy, Donald A. Richards, Peter Muscarella, Alicia Mattson, Sharona Ross, Patrick J. Flynn
Publikováno v:
Journal of Pancreatic Cancer
Journal of Pancreatic Cancer, Vol, Iss, Pp-(2021)
Journal of Pancreatic Cancer, Vol, Iss, Pp-(2021)
Purpose: GI-4000, a series of recombinant yeast expressing four different mutated RAS proteins, was evaluated in subjects with resected ras-mutated pancreas cancer. Methods: Subjects (n?=?176) received GI-4000 or placebo plus gemcitabine. Subjects' t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa63df95c91c87c53d92c83e4ec82c36
https://pubmed.ncbi.nlm.nih.gov/33786412
https://pubmed.ncbi.nlm.nih.gov/33786412
Autor:
Pallavi Sachdev, Vicky Makker, Marcia S. Brose, Ana Oaknin, Mark Messing, Antonio Casado Herraez, Emmett V. Schmidt, Daniel E. Stepan, Christopher DiSimone, Margarita Romeo, Raquel Bratos, Carol Aghajanian, Allen Lee Cohn, James W. Mier, Robert Orlowski, Corina E. Dutcus, Jane Wu, Matthew H. Taylor, Robert Shumaker
Publikováno v:
Journal of Clinical Oncology
Scientia
Scientia
PURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793cb8c5e2eacb838cdb56ab05a426c5
https://pubmed.ncbi.nlm.nih.gov/32167863
https://pubmed.ncbi.nlm.nih.gov/32167863